RT Journal Article
SR Electronic
T1 Excess deaths in Spain during the first year of the COVID–19 pandemic outbreak from age/sex–adjusted death rates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20159707
DO 10.1101/2020.07.22.20159707
A1 Martín-Olalla, José María
YR 2021
UL http://medrxiv.org/content/early/2021/06/25/2020.07.22.20159707.abstract
AB The Eurostat records of weekly deaths disaggregated by AGEGRP5 (five–year age groups) and sex group in Spain have been analyzed to build the age/sex–specific weekly death rates and the age/sex–adjusted weekly death rate and to infer the predicted death rate, the excess death rate and the excess deaths during the first year (52–week) of the pandemic. Adjusted rates were computed extending the last available population structure back in time to assess the death rates that should have been observed in the past with the present population structure.Age/sex–adjusted, 52–week death rate had not been as high as the observed rate 10.67 × 10−3 in the past 13 years.Poisson regression predicted a death rate of 8.81 × 10−3 which makes an excess of 1.86 × 10−3 (P − score = 21.2% and z − score = 11.9) with an unbiased standard deviation of the residuals equal to 156 × 10−6. This translates into 88 242 excess deaths (46 695 males and 41 532 females) with an unbiased standard deviation of the residuals equal to 7396 deaths.COVID–19 deaths (73 520) accounts for 83% of the total excess. Taking into account the 9772 COVID–19 suspected deaths that occurred in nursing homes and care facilities during the spring of 2020 it is only 4950 (5.6% of excess deaths) that remains unattributed.The infection rate during the first year of the pandemic is estimated in 17 % of population after comparing the ENE–COVID seroprevalence, the excess deaths at the end of the spring 2020 and the excess deaths at the end of the first year of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:public information only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this manuscript come from public records.